High Glucose

1. Rosenbloom AL. The cause of the epidemic of type 2 diabetes in children. Curr Opin Endocrinol Diab 2000; 7:191-6.

2. Rosenbloom Al, Joe JR, Young RS, Winter WE. The emerging epidemic of type 2 diabetes mellitus in youth. Diabetes Care 1999; 22:345-54.

3. UK Prospective Diabetes Study group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352:837-53.

4. Haffner SM, Stern MP, Hazuda P, et al. Cardiovascular risk factors in confirmed prediabetic individuals. N Engl J Med 1990; 263:2893-8.

5. Abdella N, Salman A, Moro M. Classical microangiopathic diabetic complications in the absence of overt diabetes mellitus. Diab Res Clin Pract 1990; 8:283-6.

6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-7.

7. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Eng J Med 1988; 318:1315-21.

8. Greene DA, Lattimer SA, Sima AAF. Pathogenesis and prevention of diabetic neuropathy. Diabetes/ Metab Rev 1988; 4:201-21.

9. Bursell SE, Clermont AC, Aiello LP, et al. High dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22:1245-51.

10. Bursell SE, King GL. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications. Diab Res Clin Pract 1999; 45:169-82.

11. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998; 21:1551-9.

12. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-7.

13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.

14. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21:69-75.

15. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandanavian simvastatin survival study (4S). Diabetes Care 1997; 20:614-20.

16. Sacks FM, Pfeffer MA, Moye LA, et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.

17. Hansson L, Zanchetti A, Carruthers SG, et al. The effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998; 351:1755-62.

18. Turner RC, Millins H, Neil HA, et al. for the United Kingdom prospective diabetes study group. Risk factors for coronary disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study. BMJ 1998; 316:823-8.

19. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22:696-9.

20. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-40.

21. The DECODE study group on behalf of the European diabetes epidemiology group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354:617-25.

22. Groeneveld Y, Petri H, Hermans J, Springer MP. Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabet Med 1999; 16:2-13.

23. The Diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.

24. Krolweski AS, Laffel LMB, Krolweski M, et al. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin dependent diabetes mellitus. N Eng J Med 1995; 332: 1251-5.

25. Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications? J Diabet Complications 1995; 9:25-30.

26. The diabetes control and complications trial research group. The absence of a glycemic threshold for the development of long-term complications: THE perspective of the diabetes control and complications trial. Diabetes 1996; 45:1289-98.

27. The Diabetes control and complications trial/epidemiology of diabetes interventions and Complications research group. Retinopathy and nephropathy in patients with type1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9.

28. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab Res Clin Pract 1995; 28:103-17.

29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.

30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.

31. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care 1998; 21:2180-4.

32. Fioretto P, Steffes MW, Sutherland DER, et al. Reversal of lesions of diabetic nephropathy after pancreatic transplantation. N Eng J Med 1998; 339:69-75.

33. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2001; (Suppl. 1):S77-9.

34. Pettit DJ, Baird HR, Aleck KA, et al. Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Eng J Med 1983; 308:242-5.

35. Canadian Diabetes Association. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998; 159 (Suppl. 8):SS18-9.

36. Abraira C, Colwell JA, Nuttall F, et al, for the VA CSDM Group. Cardiovascular events and correlates in the Veterans affairs diabetes feasibility trial. Arch Intern Med 1997; 157:181-8.

37. Tests of Glycemia in Diabetes. The American Diabetes Association. Diabetes Care 2001; 24:S80-2.

38. Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:979-82.

39. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin dependent diabetes mellitus can be predicted from self -blood monitoring blood glucose data. J Clin Endo Metab 1994; 79:1659-62.

40. Marshall SM, Barth JH. Standardization of HbAic measurements—a consensus statement. Diabetic Med 2000; 17:5-6.

41. Lytken Larsen M, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990; 323:1021-5.

42. Chase P, Lockspeiser T, Peery B, et al. The impact of the diabetes control and complications trial and Humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24:430-4.

43. Cooppan R. Diabetes in the elderly: implications of the diabetes control and complications trial. Comprehen Ther 1996; 22:286-90.

44. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of RBX is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthamol Vis Sci 2006; 47:86-92.

45. Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1 year, randomized, placebo-controlled, double blind clinical trial. Clin Ther 2005; 27:1164-80.

46. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 2003; 361:2005-16.

47. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atovarstatin in type 2 diabetes in the Collaborative Atovarstatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial. Lancet 2004; 364:685-96.

48. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications(DCCT/EDIC). Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-53.

49. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus:metaanalysis of randomized trials. Am Heart J 2006; 152:27-38.

50. American Diabetes Association. Diabetes Care. 2006; 29:(Suppl.):S10.

51. European Diabetes Policy Group. Diabetic Med. 1999; 16:716-73.

52. Sacks DB for the ADA/EASD/IDF Working Group of the HbA1c Assay. Global Harmonization of Hemoglobin A1c. Clin. Chem 2005; 51:681-3.

53. The Diabetes Research in Children Network (DirecNet) Study Group. Comparison of finger stick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a DirecNet Study. Pediatric Diabetes 2005; 6:13-6.

Spiritual Weight Loss Mentality

Spiritual Weight Loss Mentality

Awesome Ways To Get Over Your Mentality That Keeps you Overweight! This Book Is One Of The Most Valuable Resources In The World When It Comes To Results In Your Slim-down and Health Efforts! Day in day out we keep ourselves absorbed with those matters that matter the most to us. A lot of times, it might be just to survive and bring in some money. In doing so we at times disregard or forget about the extra matters that are essential to balance our lives. They’re even more essential to supply real meaning to our world. You have to pay attention to your wellness.

Get My Free Ebook

Post a comment